Britain and America have forged a key commercial pact that will preserve no import taxes on UK pharmaceutical exports going into the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to boost expenditure on drugs through the public health system. This pledge ensures that import taxes on these crucial exports will remain at zero for a duration of the next three years.
This agreement is in response to earlier warnings to hike tariffs on branded drug imports, with potential rates discussed up to one hundred percent.
"This deal between the United Kingdom reinforces the international landscape for new treatments and establishes long-overdue balance to U.S.–U.K. pharmaceutical trade," a release noted.
Trade Importance
Pharmaceuticals represent one of the UK's biggest goods shipped to the US, which is by far the primary buyer for leading companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period leading up to last September, the UK shipped drugs worth billions to the US. This value accounted for nearly one-fifth of British export trade in that span.
"This agreement protects work, boosts capital expenditure and facilitates the UK to become a international leader for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The agreement entails several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to increase total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The amount drug companies must pay back to the NHS to control costs will be limited at fifteen percent. Last year, refunds exceeded twenty percent.
Industry Background
The pact follows a long-running tension between the sector and the British authorities over drug pricing and approval rates.
This friction were heightened by claims that American patients were paying a premium for the same drugs than people in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been halted or cancelled, while substantial investments have been directed toward US facilities.
The Science Minister publicly accepted that the NHS must spend more on treatments, noting that its spending on drugs had shrunk as a share of its overall budget over the past decade.
